Manual subcutaneous pushes require nurses to be physically present, applying constant pressure for several minutes. On-body systems automate this, untethering nurses to attend to other patients or tasks. This improves clinic workflow efficiency and reduces the physical strain and professional burden on nursing staff.
The drop in systemic administration reactions from 25% (IV) to 1.5% (on-body injector) is a "game changer." It shifts the initial conversation with new patients from managing fear about a common, scary reaction to focusing on the treatment's benefits, improving the psychological start to therapy.
Gaining FDA approval for a new delivery system like an on-body injector requires more than showing it works. The Iroclia trial for subcutaneous isatuximab had to meet dual primary endpoints, proving non-inferiority in both clinical efficacy (response rates) and pharmacokinetics (drug levels in the blood), setting a high regulatory bar.
The development of on-body delivery systems for complex biologics is more than an incremental improvement. It represents a crucial technological step toward moving cancer care from the clinic into a patient's home, a long-sought goal that could dramatically increase patient convenience and access to care.